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Abstract: Heterocycle-containing cyclic peptides are promis-
ing scaffolds for the pharmaceutical industry but their chemical
synthesis is very challenging. A new universal method has been
devised to prepare these compounds by using a set of
engineered marine-derived enzymes and substrates obtained
from a family of ribosomally produced and post-translation-
ally modified peptides called the cyanobactins. The substrate
precursor peptide is engineered to have a non-native protease
cleavage site that can be rapidly cleaved. The other enzymes
used are heterocyclases that convert Cys or Cys/Ser/Thr into
their corresponding azolines. A macrocycle is formed using
a macrocyclase enzyme, followed by oxidation of the azolines
to azoles with a specific oxidase. The work is exemplified by the
production of 17 macrocycles containing 6–9 residues repre-
senting 11 out of the 20 canonical amino acids.
Macrocyclic peptides show high target affinity, bioavaila-
bility, and stability and thus have enjoyed considerable use as
therapeutics.[1] The conformational constraints on macro-
cyclic peptides imposed by the incorporation of heterocycles
have been suggested to contribute to higher receptor affinity
by reducing the entropic penalty paid for immobilization.[2]
The testing and development of such constrained macrocyclic
compounds is hindered by the technical difficulties and the
high cost of their chemical synthesis on a useful scale.[3]
Several cyanobacteria have been found to produce diverse
bioactive azole-containing cyclic peptides, the cyanobactins,
with the most well-known being the patellamides. These
conformationally constrained peptides are made by post-
translational tailoring of ribosomal peptides.[4] Using enzymes
and substrates from the patellamide, trunkamide, aestuara-
mide, microcyclamide, and tenuecyclamide biosynthetic path-
ways, we present a robust scalable in vitro route for the
production of azoline-containing cyclic peptides (Scheme 1).
The thiazoline-containing products can be further treated
with oxidases derived from the Cyanothece PCC 7425 or
Arthrospira platensis to obtain thiazoles which are less prone
to spontaneous epimerization at the adjacent stereocenters.[5]
The route is flexible as we can use either the cysteine- (or
selenocysteine-) specific heterocyclases, TruD (Prochlor-
on sp.) or LynD (Lyngbya sp.) which only slowly process Ser
or Thr,[6,7] or the heterocyclases PatD (Prochloron sp.), MicD
(M. aeruginosa), or TenD (N. spongiaeforme var. tenue) that
readily process Thr, Ser, Se-Cys, and Cys (Scheme 2, Fig-
ure S1). Although we have used PatGmac
[8] (from the patell-
amide pathway) as the macrocyclase, it will be straightfor-
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ward to introduce macrocyclases from other organisms which
are predicted to macrocyclize different sized rings.
We use a modified substrate PatE(core sequence) with a single
core peptide sequence and a histidine tag at the C-terminus to
aid the purification. PatE natural peptides may contain one or
more core sequences; each is flanked at the N-terminus with
a protease cleavage signal and at the C-terminus with PatGmac
signal. We can overexpress such peptides to a high level in
E. coli (100–200 mgL1) and with our protocol solubilize the
protein from inclusion bodies.[6a]
We have shown elsewhere that the N-terminal leader
sequence can be shortened and still retain the essential
recognition determinants for the heterocyclase.[6a] After
heterocyclization the thiazoline- (or oxazoline-) containing
substrate must be processed prior to macrocyclization involv-
ing cleavage of the N-terminal leader. Analysis of chemical
reactivity implies that epimerization at Ca precedes oxidation
but follows heterocyclization; however, the exact sequence of
the chemical reactions in vivo remains unknown. To provide
insight into the epimerization reaction, a heterocyclized (two
thiazolines) perdeuterated PatE(ITACITFC) (
2H-PatE(ITACITFC))
sample was prepared and an 1H NMR spectrum was imme-
diately recorded. In the event of a spontaneous epimerization
reaction, exchange of peptide Ca deuterium with hydrogen
from the solvent would be observed as an increase in the
NMR signal. No increase in the signal was observed
immediately after heterocyclization or on the same sample
following incubation at pH 9.0 for seven days (Figure S2).
This suggests epimerization, if it is spontaneous, will occur in
the macrocycle as previously predicted.[9]
PatA, the cognate protease which cleaves after the
GLEAS motif is extremely slow in vitro and thus not suitable
for the production of milligram quantities of material or
a large number of variant patellamides.[10] It has been shown
that it is possible to insert at least six residues between
GLEAS and the core peptide without affecting the hetero-
cyclization reaction.[6a,b] The introduction of specific protease
sites is a well-established tool in protein chemistry.[11] We,
therefore, have developed a number of solutions to replace
PatA by inserting other protease sites between the core and
the GLEAS motif. Insertion of a single Lys residue allows
trypsin to cut very rapidly (Figure S3) but of course is not
suitable for core sequences containing Lys or Arg unless the
subsequent residue is Pro (or possibly a heterocyclized
residue). Tobacco etch virus (TEV) protease is very efficient
but as its recognition site is ENLYFQ›G it changes the first
residue of the core to Gly (TEV protease tolerates other
residues except proline) (Figure S4).[12] GluC selectively
cleaves peptide bonds C-terminal to Glu, but in our studies
it was poor in terms of speed and yield.
We used PCR Based Mutagenesis with the In-Fusion HD
Cloning System (Clontech Laboratories, USA) to generate
a series of PatE substrates. Alternatively, we have developed
new vectors encoding the PatE peptide, with TEV protease or
trypsin N-terminal cleavage sites, where we can incorporate
short oligonucleotides, which cover only the core peptide
sequence, into the vector by simple annealing and thus
facilitate the design of the final products (Figures S5 and S6).
Oxidation of the thiazoline rings in 1 to thiazoles was
achieved using Cyanothece oxidase (Thcoxi) in the presence of
FMN cofactor (Figure S7). With this protein we did not
observe activity on the heterocycle-containing linear peptides.
In contrast, we could demonstrate oxidation of both linear
PatE and macrocyclic product with the highly homologous
enzyme Apoxi, from A. platensis (Figures S8 and S9). The
oxidation of the heterocycles in linear substrates has pre-
viously been characterized in the thiazole/oxazole-modified
microcins (TOMMS) pathway.[13] The dehydrogenation reac-
tion could alternatively be carried out at a much slower rate
Scheme 1. A schematic representation of the in vitro biosynthesis of
azol(in)e-based cyclic peptides. The substrate PatE is first processed
with either TruD/LynD (which convert Cys into thiazoline) or PatD/
MicD/TenD (which convert Cys, Ser, and Thr into thiazoline, oxazoline,
and methyl oxazoline, respectively). The leader sequence of the
purified and processed substrate is then cleaved off with a suitable
protease. The cleaved core peptide is purified and cyclized with
PatGmac. Thiazoline rings can be oxidized to thiazoles with the oxidases
from Cyanothece (Thcoxi) or A. platensis (Apoxi).
Scheme 2. Heterocyclization reaction of cysteine, serine, or threonine
residues.
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by reaction with excess MnO2 in dichloromethane for three
days at 28 8C. Circular dichroism measurements showed that
the stereochemistry of the final product obtained by chemical
oxidation was identical to that of the natural product
ascidiacyclamide (Figure S10). This indicates that epimeriza-
tion had occurred spontaneously at the stereocenters adjacent
to the thiazolines as previously predicted.[9] It remains unclear
whether and to what extent the different oxidases are
sensitive to the stereochemical context of the heterocycle
(has epimerization occurred and has the macrocycle formed).
Final products are purified from PatGmac reaction mixtures
using SPE followed by HPLC.
The method is scalable and 1–2 mg of highly pure final
product can be obtained from each 100 mL macrocyclization
reaction containing 100 mm of cleaved and processed PatE.
Using this approach, we have successfully synthesized,
isolated, and characterized a small library of azol(in)e-
containing cyclic peptides of six to nine amino acids
(compounds 1–17; Table 1). These compounds have been
generated from variable core sequences with 11 out of the 20
canonical amino acids. NMR spectra and LCMS data were
recorded for compounds 1, 3, 4, and 7 while LCMS and
MSMS analyses were used to confirm the identity of the other
compounds (NMR data are listed in Tables S1–S4, NMR and
LCMS spectra are shown in Figures S11–S43). Compound 1 is
the reduced form of ascidiacyclamide and was previously
isolated, for the first time, by our group from a specimen of
Lissoclinum patella. Figure S12a shows the stacked 1H NMR
spectra of the natural and biosynthetic materials.
A successful in vivo approach[14] to produce highly
modified cyanobactins has been reported and shown to be
capable of producing a cyanobactin with a nonnatural amino
acid. Our in vitro approach has some key advantages over the
in vivo approach. The in vitro approach allows the same
precursor peptide to give different final products (for
example by processing one portion with PatD and another
portion with TruD or by using oxidase or not). This avoids the
complex protein-engineering approach that would be
required in vivo. The in vitro process is quicker as it uses
more active proteases and tunes the conditions for each
reaction, rather than accepting a single compromise. The in
vitro approach is essential for the production of compounds
that can inhibit the growth of the in vivo host (antibacterial).
Finally the in vitro approach allows facile real-time monitor-
ing and intervention. On the other hand, the in vivo approach
has its merits by being much cheaper and less labor intensive
(no need for enzyme purification).
From a purely synthetic viewpoint, macrocyclic peptides
are challenging as macrocyclization is often low-yielding
requiring reactions to be carried out with low concentrations
in large reaction volumes to favor macrocyclization over
oligomerization.[15] Biosynthetic alternatives include sortase-
mediated ligation, but this requires an LPXTGmotif at the C-
terminus and oligo-G at the N terminus, which are incorpo-
rated in the final cyclic peptide.[16] Similarly protein splicing
requires the synthesis of a linear peptide containing intein,
signals for which are again incorporated in the final peptide
unless additional steps are carried out. This method is often
inefficient and > 30% of sequences cannot be cyclized.
Problems associated with the chemical synthesis of thiazo-
lines and oxazolines include the likely racemization at the
labile a-carbon adjacent to the thiazoline, the low yield, and
the side reactions.[17]
In summary, our approach will open up the synthesis of
large numbers of cyanobactin variants in biologically useful
quantities. This will in turn revolutionize their application in
biology and in the longer term therapeutic discovery, which is
currently stalled because no useful or generally applicable
routes exist to such molecules.
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